Olean man sentenced to 3-9 years for hit-and-run death
Breaking News
Olean man sentenced to 3-9 years for hit-and-run death
KELLEN M. QUIGLEY kquigley@oleantimesherald.com 
August 27, 2025
OLEAN — An Olean man has been sentenced to three to nine years in state prison for a 2023 hit-and-run incident on Seneca Avenue that resulted in a wom...
Home Online Features Akeso's Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis
Akeso’s Ebdarokimab ( IL – 12/IL – 23 Dual – Targeted Monoclonal Antibody) Approved in China for Moderate – to – Severe Plaque Psoriasis
Press Releases
Akeso, Inc.  
April 18, 2025

Akeso’s Ebdarokimab ( IL – 12/IL – 23 Dual – Targeted Monoclonal Antibody) Approved in China for Moderate – to – Severe Plaque Psoriasis

HONG KONG, April 18, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social